ProPhase Labs announces plans to initiate clinical trial of Equivir OTC

ProPhase Labs announced that its wholly-owned subsidiary, ProPhase BioPharma, is initiating a randomized, placebo-controlled clinical trial of Equivir OTC to evaluate its effect on upper respiratory tract infections. Vedic Lifesciences, a leading clinical research organization, is contracted to conduct the combination prophylactic and therapeutic study, which will be conducted at 12 sites, with enrollment planned to commence in March 2023. ProPhase BioPharma announced a licensing agreement for Equivir in the second quarter of 2022. In the second half of 2022, PBIO completed Equivir compound formulation and claim aggregation to optimize future commercialization and marketing initiatives. PBIO also completed compound claim substantiation, clinical trial protocol development and initiated its contract research organization recruitment protocol in late 2022. The Company expects trial completion in the third quarter of 2023 and will seek to launch Equivir as an over-the-counter dietary supplement in the fourth quarter of 2023.